MedPath

Deucravacitinib

Generic Name
Deucravacitinib
Brand Names
Sotyktu
Drug Type
Small Molecule
Chemical Formula
C20H22N8O3
CAS Number
1609392-27-9
Unique Ingredient Identifier
N0A21N6RAU
Background

Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target. This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered cholesterol and triglyceride levels and liver and kidney dysfunction.

Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis. It was later approved by Health Canada in November 2022 and by the European Medicines Agency in March 2023.

Indication

Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is not recommended for use in combination with other potent immunosuppressants.

Associated Conditions
Severe Plaque psoriasis, Moderate Plaque psoriasis
Clinical Trials
Related News

Accropeutics' Oral TYK2/JAK1 Inhibitor Shows Strong Efficacy in Phase 2 Psoriasis Trial

• AC-201, an oral selective TYK2/JAK1 inhibitor, met its primary endpoint with up to 74.3% of patients achieving PASI-75 responses at week 12 across all three dosing regimens tested. • The drug demonstrated a favorable safety profile with no serious adverse events or discontinuations, positioning it as a potentially competitive option in the growing market for oral psoriasis treatments. • Based on these positive Phase 2 results, Accropeutics plans to advance AC-201 into Phase 3 development for plaque psoriasis, with potential applications in other autoimmune conditions.

Lilly's Olumiant Shows Promise in Preserving Beta Cell Function in Type 1 Diabetes

• Phase 2 BANDIT trial demonstrates Eli Lilly's Olumiant (baricitinib) can slow progression of type 1 diabetes by preserving insulin-producing beta cell function over 48 weeks of treatment. • Patients receiving Olumiant required significantly less insulin therapy and experienced decreased blood glucose fluctuations compared to placebo, potentially reducing treatment burden. • Researchers identify TYK2 inhibition as another promising approach for type 1 diabetes treatment, with an FDA-approved psoriasis drug potentially offering a dual mechanism to protect beta cells and reduce inflammation.

Robust Pipeline of 80+ Therapies Advancing in Psoriasis Treatment Landscape

• DelveInsight's 2025 Psoriasis Pipeline Report reveals over 80 companies developing 80+ pipeline therapies, highlighting significant R&D investment in this therapeutic area. • Promising treatments in development include topical roflumilast (Arcutis Biotherapeutics) in Phase III trials and GSK2982772 (GlaxoSmithKline), a novel RIPK1 inhibitor in Phase I development. • Alumis Inc. has initiated a long-term extension study for ESK-001 in moderate to severe plaque psoriasis patients, evaluating safety, efficacy, and durability of response over 24 weeks.

Protagonist's Icotrokinra Shows Promising Results in Ulcerative Colitis and Psoriasis Trials

• Protagonist Therapeutics and Johnson & Johnson's oral peptide icotrokinra achieved 63.5% clinical response rate in ulcerative colitis patients at Week 12, significantly outperforming placebo in the Phase 2b ANTHEM-UC study. • In Phase 3 trials for plaque psoriasis, icotrokinra demonstrated superior efficacy to both placebo and Bristol-Myers Squibb's Sotyktu, with 65% of patients achieving PASI 90 response by Week 24. • The successful clinical outcomes have driven Protagonist's stock up nearly 46%, marking a financial turnaround for the company which reported its first profit of $275 million in 2024 after years of losses.

Landmark CheckMate 816 Trial: Nivolumab-Chemotherapy Combo Shows Survival Benefit in Resectable Lung Cancer

• Neoadjuvant nivolumab plus platinum-doublet chemotherapy demonstrates statistically significant overall survival improvement in resectable non-small cell lung cancer patients compared to chemotherapy alone. • The groundbreaking phase 3 CheckMate 816 trial establishes the first neoadjuvant immunotherapy combination to achieve significant survival benefits, with previously reported 24% pathological complete response rate. • The treatment combination maintains a consistent safety profile with no new concerns, while showing improved efficacy in both neoadjuvant and perioperative settings for resectable NSCLC patients.

Alumis and Acelyrin Announce Merger to Create $737M Clinical-Stage Biopharma Company

• Alumis and Acelyrin have agreed to merge in an all-stock transaction, creating a combined entity with $737 million in cash runway extending into 2027. • The merged company will retain the Alumis name and prioritize development of two TYK2 inhibitors targeting conditions including psoriasis, lupus, and multiple sclerosis. • Acelyrin's thyroid eye disease drug lonigutamab is included in the deal but will undergo strategic review to assess its market differentiation potential.

Bristol Myers Squibb Announces $2 Billion Cost-Cutting Plan Amid Patent Cliff Challenges

• Bristol Myers Squibb unveiled plans to reduce annual expenses by an additional $2 billion by 2027, expanding on previous cost-cutting measures that affected 2,200 employees. • The company projects a 6% revenue decline to $45.5 billion in 2025, falling short of analyst expectations as key products face generic competition. • Despite challenges, BMS's growth portfolio, including newer medicines like Camzyos and Breyanzi, showed strong performance with 21% growth in 2024.

FDA Approves Lilly's Omvoh (mirikizumab) for Crohn's Disease

• The FDA has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for treating moderately to severely active Crohn's disease in adults, expanding its use for inflammatory bowel disease. • The approval was based on the VIVID-1 trial, which showed significant clinical remission and endoscopic response rates compared to placebo after one year of treatment. • Omvoh is the first biologic in over 15 years with Phase 3 two-year efficacy data at launch, demonstrating long-term disease control and visible healing of the intestinal lining. • Lilly has submitted marketing applications globally, aiming to provide a new treatment option for Crohn's patients and is working with insurers to enable patient access.

Advancements and Challenges in Clinical Trials: A 2024 Overview

2024 has seen significant progress in clinical trials across various diseases, including neurodegenerative diseases, cancer, and eye diseases, with several treatments moving into pivotal Phase III trials. However, the year also witnessed challenges, including missed endpoints in trials targeting motor neurone disease and setbacks in depression treatment trials.

Breyanzi Receives Positive CHMP Opinion for Follicular Lymphoma Treatment in EU

• The CHMP has recommended Breyanzi for treating relapsed or refractory follicular lymphoma (FL) in adults after two or more prior systemic therapies. • The recommendation is based on the Phase 2 TRANSCEND FL study, which showed a 97.1% overall response rate and a 94.2% complete response rate. • Breyanzi demonstrated rapid and durable responses, with 75.7% of patients in response at 18 months, and a consistent safety profile in clinical trials. • The European Commission will review the CHMP recommendation, with a final decision expected within approximately two months.

BMS's Sotyktu Demonstrates Success in Phase III Psoriatic Arthritis Trials

Bristol Myers Squibb's Sotyktu has achieved positive results in two Phase III clinical trials for psoriatic arthritis, marking a significant advancement in treatment options for this chronic inflammatory condition. This development expands the potential therapeutic applications of Sotyktu beyond its existing indications.

XBiotech Halts Rheumatology Program Following Phase II Trial Irregularities with Natrunix

• XBiotech has paused its rheumatology program after a Phase II trial of Natrunix for rheumatoid arthritis failed to meet its primary endpoint. • The trial, involving 230 subjects, was compromised by substantial irregularities, including multiple enrollments of the same subjects. • The company's stock value dropped by 27% following the announcement, and additional studies in rheumatology are now on hold. • Law firms are investigating XBiotech for potential securities fraud due to the handling and disclosure of the trial's issues.

Sotyktu Meets Primary Endpoints in Phase 3 Psoriatic Arthritis Trials

• Bristol Myers Squibb's Sotyktu (deucravacitinib) demonstrated significant efficacy in two Phase 3 trials for active psoriatic arthritis (PsA). • The POETYK PsA-1 and PsA-2 trials met their primary endpoint, showing a greater proportion of Sotyktu-treated patients achieved ACR20 response at Week 16 compared to placebo. • Both trials also met key secondary endpoints related to PsA disease activity, with a safety profile consistent with previous studies. • Sotyktu, a TYK2 inhibitor, could potentially become a novel oral treatment option for PsA, addressing the need for safe and effective therapies.

Vertex's ALYFTREK Approved by FDA as Next-Generation Cystic Fibrosis Treatment

• The FDA has approved Vertex's ALYFTREK for cystic fibrosis (CF) in patients aged 6 years and older with specific genetic mutations. • ALYFTREK is a once-daily triple combination therapy, offering a more convenient dosing schedule compared to existing treatments. • Clinical trials demonstrated ALYFTREK's non-inferiority to TRIKAFTA in lung function and significant improvement in sweat chloride levels. • The drug's label includes a boxed warning for potential liver injury, necessitating regular liver function monitoring.

Gilead's Trodelvy Receives FDA Breakthrough Therapy Designation for SCLC; Seladelpar Recommended for EU Approval

• The FDA granted Breakthrough Therapy Designation to Gilead's Trodelvy for extensive-stage small cell lung cancer (ES-SCLC) after platinum-based chemotherapy, based on promising results from the TROPiCS-03 study. • Gilead will collaborate with Terray Therapeutics to discover and develop novel, small molecule therapies across multiple targets, leveraging Terray's tNova platform. • The European Medicines Agency's CHMP recommended approval of Gilead's seladelpar for primary biliary cholangitis (PBC) in combination with UDCA or as monotherapy.

Deucravacitinib Demonstrates Long-Term Efficacy and Safety in Psoriasis Treatment

• A 3-year integrated analysis of phase 3 trials shows deucravacitinib maintains a consistent safety profile in moderate to severe plaque psoriasis patients. • Clinical response rates, measured by PASI 75/90 and sPGA 0/1, were sustained through 3 years of continuous deucravacitinib treatment. • The study highlights that deucravacitinib significantly improves the quality of life for patients, reducing the impact of psoriasis on daily activities. • Deucravacitinib's effectiveness remains consistent regardless of prior apremilast or biologic use, offering a versatile treatment option.

Protagonist Therapeutics' Oral Icotrokinra Achieves Positive Phase 3 Results for Plaque Psoriasis

• Protagonist Therapeutics' icotrokinra, an oral peptide drug, demonstrated significant skin clearance in Phase 3 trials for moderate-to-severe plaque psoriasis. • The ICONIC-LEAD study showed 65% of patients achieved clear skin (IGA 0 or 1) at week 16 with icotrokinra, compared to 8% in the placebo group. • Icotrokinra targets the IL-23 receptor and aims to provide a less invasive, oral alternative to injectable biologics for psoriasis treatment. • Protagonist will receive a $115 million milestone payment from Johnson & Johnson following the successful completion of the Phase 3 study.

Icotrokinra Shows Promise as Oral Treatment for Plaque Psoriasis in Phase 3 Trial

• Icotrokinra, an oral peptide drug blocking the IL-23 receptor, demonstrated significant clearance of psoriatic plaques in a Phase 3 trial. • 65% of patients achieved clear skin (IGA score of 0 or 1) at week 16 with icotrokinra, compared to 8% in the placebo group. • 50% of icotrokinra patients achieved a PASI 90 score at week 16, indicating a 90% improvement from baseline, versus 4% in the placebo group. • Developed by Protagonist Therapeutics in collaboration with Johnson & Johnson, icotrokinra aims to offer an effective, less invasive oral alternative to injectable therapies.

Johnson & Johnson's Oral IL-23 Inhibitor Icotrokinra Shows Promise in Phase 3 Psoriasis Trials

• Johnson & Johnson's oral drug icotrokinra demonstrated significant skin clearance in Phase 3 trials for moderate-to-severe plaque psoriasis. • In the ICONIC-LEAD study, icotrokinra achieved clear or almost clear skin in approximately two-thirds of participants after four months. • Icotrokinra targets the IL-23 receptor, similar to injectable drugs like Skyrizi and Tremfya, offering a convenient oral administration. • J&J is preparing regulatory submissions based on these results and plans further studies in psoriatic arthritis and ulcerative colitis.

J&J's Oral IL-23 Inhibitor Icotrokinra Achieves Positive Phase 3 Results in Psoriasis

• Johnson & Johnson's icotrokinra met primary endpoints in the ICONIC-LEAD phase 3 trial, demonstrating significant skin clearance in psoriasis patients. • After 16 weeks, 64.7% of patients achieved clear or almost clear skin (IGA 0/1), and 49.6% showed a 90% or greater improvement in PASI score. • Icotrokinra's tolerability profile was consistent with previous phase 2 studies, with similar adverse event rates compared to placebo. • J&J plans to submit icotrokinra for regulatory approval, positioning it as a potential oral alternative to injectable biologics for psoriasis.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy